| Neurotrope is a biopharmaceutical company with product candidates in pre-clinical and clinical development. Co. is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. Co. is also developing bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease. In addition, Co. is also in the early stages of testing bryostatin activity which may lead to applications in Leukemia and Lymphoma. We show 13 historical shares outstanding datapoints in our NTRP shares outstanding history coverage, used to compute NTRP market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NTRP market cap history over the course of time is important for investors
interested in comparing NTRP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NTRP versus a peer is one thing; comparing
NTRP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NTRP can fluctuate over the course of history.
With this page we aim to empower investors researching NTRP by allowing them to research the NTRP market cap history.